UBS AM’s Stemline Therapeutics, Inc. STML Stock Holding History

UBS AM’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-38,917	Closed	-$188K	–	2578
2020 Q1	$188K	Sell	38,917 -293	-0.7%	-$1.9K	﹤0.01%	2293
2019 Q4	$417K	Buy	39,210 +7,745	+25%	+$76.9K	﹤0.01%	2296
2019 Q3	$328K	Buy	31,465 +13,678	+77%	+$179K	﹤0.01%	2431
2019 Q2	$272K	Hold	17,787	–	–	﹤0.01%	2439
2019 Q1	$229K	Buy	17,787 +17,600	+9,412%	+$199K	﹤0.01%	2412
2018 Q4	$1.78K	Hold	187	–	–	﹤0.01%	2734
2018 Q3	$3.1K	Hold	187	–	–	﹤0.01%	2716
2018 Q2	$3K	Buy	+187	New	+$3.34K	﹤0.01%	2735

UBS AM's STML Position: Q2 2020 in Review

UBS AM sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 38,917 shares — an estimated $188K sold.

UBS AM first reported a position in STML in Q2 2018 and held it in 8 quarters. The position peaked at $417K in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

UBS AM reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
UBS AM sold 38,917 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $188K.
UBS AM first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 8 quarters.
UBS AM's Stemline Therapeutics, Inc. position peaked at $417K in Q4 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on UBS AM's 13F filing for Q2 2020, filed 14 Aug 2020.